BR112023004262A2 - Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio - Google Patents

Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Info

Publication number
BR112023004262A2
BR112023004262A2 BR112023004262A BR112023004262A BR112023004262A2 BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2 BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2
Authority
BR
Brazil
Prior art keywords
binding site
methods
mass spectrometry
hydrogen exchange
exchange mass
Prior art date
Application number
BR112023004262A
Other languages
English (en)
Inventor
Zhang Sisi
Xiao Hui
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112023004262A2 publication Critical patent/BR112023004262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS PARA IDENTIFICAÇÃO DO SÍTIO DE LIGAÇÃO USANDO ESPECTROMETRIA DE MASSA DE TROCA DE HIDROGÊNIO. A presente invenção refere-se a métodos para identificar um sítio de ligação entre um produto farmacêutico de proteína e uma proteína de célula hospedeira (HCP) usando espectrometria de massa de troca de hidrogênio. O presente pedido também fornece métodos para modificar produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs. Além disso, o presente pedido fornece métodos para bloquear o sítio de ligação identificado em produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs.
BR112023004262A 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio BR112023004262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077220P 2020-09-11 2020-09-11
PCT/US2021/049975 WO2022056336A1 (en) 2020-09-11 2021-09-11 Methods for binding site identification using hydrogen exchange mass spectrometry

Publications (1)

Publication Number Publication Date
BR112023004262A2 true BR112023004262A2 (pt) 2023-04-04

Family

ID=78333247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004262A BR112023004262A2 (pt) 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Country Status (11)

Country Link
US (1) US20220082571A1 (pt)
EP (1) EP4211255A1 (pt)
JP (1) JP2023542858A (pt)
KR (1) KR20230066025A (pt)
CN (1) CN116490777A (pt)
AU (1) AU2021342274A1 (pt)
BR (1) BR112023004262A2 (pt)
CA (1) CA3194955A1 (pt)
IL (1) IL301234A (pt)
MX (1) MX2023002924A (pt)
WO (1) WO2022056336A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604345B2 (ja) * 2000-12-21 2011-01-05 住友化学株式会社 タンパク質のｎ末端のアミノ酸配列決定方法
CA2436503A1 (en) * 2001-02-01 2002-08-08 Huw A. Davies Improved methods for protein identification, characterization and sequencing by tandem mass spectrometry
AU2003221860A1 (en) * 2002-04-10 2003-10-27 The Regents Of The University Of California Improved methods for high-resolution identification of solvent-accessible amide hydrogens in polypeptides and for characterization of polypeptide structure
US7378396B2 (en) * 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
WO2009050266A2 (en) * 2007-10-19 2009-04-23 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
EP2394173B1 (en) * 2009-02-09 2015-03-25 Roche Glycart AG Immunoglobulin glycosylation pattern analysis
MX2013013054A (es) * 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
EP3387440B1 (en) * 2015-12-09 2021-05-12 F. Hoffmann-La Roche AG Method for determining the in vivo interaction mode
CN108369232B (zh) * 2015-12-09 2022-05-31 豪夫迈·罗氏有限公司 人IgG1结合多聚抗原的直接亲和力测量
US20190169675A1 (en) * 2016-08-12 2019-06-06 Lonza Ltd Proteomic analysis of host cell proteins

Also Published As

Publication number Publication date
WO2022056336A1 (en) 2022-03-17
AU2021342274A1 (en) 2023-04-27
CN116490777A (zh) 2023-07-25
EP4211255A1 (en) 2023-07-19
KR20230066025A (ko) 2023-05-12
JP2023542858A (ja) 2023-10-12
MX2023002924A (es) 2023-04-10
CA3194955A1 (en) 2022-03-17
IL301234A (en) 2023-05-01
US20220082571A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
BR112022017048A2 (pt) Anticorpos contra sars-cov-2 e métodos para usar os mesmos
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
Chen et al. Site-specific mass tagging with stable isotopes in proteins for accurate and efficient protein identification
CY1119412T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
CY1120249T1 (el) Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
BR112018002553A8 (pt) Sais de um inibidor de lsd1
BR112022001460A2 (pt) Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
NO20075635L (no) Antigenbindende molekyler som har modifiserte Fc-regioner og endret binding til Fc-reseptorer
WO2018226685A3 (en) METHODS FOR THE SENSITIZATION OF CANCER CELLS TO MEDIATED DESTRUCTION BY T-LYMPHOCYTES BY MOLECULAR PATHWAY MODULATION
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
BR112015007725A2 (pt) sistema, método e dispositivo para processamento de informação sobre interface de ar
BR112018015590A2 (pt) modulação de receptor acoplado à proteína g (gpcr) por imipridonas
JP2019506866A5 (pt)
CO6640290A2 (es) Sistema y método para personalizar solicitudes en tiempo real en una interaz de usuario
BRPI0607793A2 (pt) processo para a preparação de moduladores opióides
BR112013025629A2 (pt) padrão quantitativo para espectrometria de massa de proteínas
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112023021978A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BRPI0923582B8 (pt) método e dispositivo para análise de uma causa de recuperação elástica em um produto formado
MX2022005698A (es) Metodos y sistemas para identificar, clasificar y/o categorizar secuencias geneticas.
BR112023021561A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112023001517A2 (pt) Relatório de informações relacionadas à integridade para posicionamento